Cite

HARVARD Citation

    Thaper, D. et al. (2018). Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer. Scientific reports. 8 (1), pp. 1-9. [Online]. 
  
Back to record